R8404
Rufinamide
≥98% (HPLC), powder
Synonym(s):
1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C10H8F2N4O
CAS Number:
Molecular Weight:
238.19
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
POGQSBRIGCQNEG-UHFFFAOYSA-N
SMILES string
NC(=O)c1cn(Cc2c(F)cccc2F)nn1
InChI
1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
assay
≥98% (HPLC)
form
powder
color
white
solubility
DMSO: 9 mg/mL
originator
Novartis
storage temp.
−20°C
Quality Level
Gene Information
Looking for similar products? Visit Product Comparison Guide
General description
Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.
Application
Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.
Biochem/physiol Actions
Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Broad-spectrum anticonvulsant.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Carc. 2 - Repr. 2 - STOT SE 3
target_organs
Central nervous system
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Maria G Dahlin et al.
Neuropediatrics, 43(5), 264-270 (2012-09-04)
We examined the influence of age and type of concomitant antiepileptic drugs (AEDs) on the pharmacokinetics of rufinamide (RUF) as well as its efficacy and safety in 51 children with refractory epilepsy. In a retrospective noninterventional survey, dose-to-concentration ratios of
Shahin Hakimian et al.
Expert opinion on pharmacotherapy, 8(12), 1931-1940 (2007-08-19)
Rufinamide (1-[2,6-difluorobenzyl]-1H-1,2,3-triazole-4-carboxamide) is a new anti-epileptic drug with a novel triazole derivative structure. The suspected mechanism of action is limitation of sodium-dependent action potentials, thought to result in a membrane stabilizing effect. Rufinamide is extensively metabolized in the liver by
Christopher S Wisniewski
The Annals of pharmacotherapy, 44(4), 658-667 (2010-03-18)
To review the pharmacology, pharmacokinetics, efficacy, and safety of rufinamide in the treatment of epileptic seizures and describe its potential place in therapy. MEDLINE (1966-January 2010) and PubMed (1966-January 2010) literature searches were conducted to identify primary literature investigating rufinamide.
Isabelle Mourand et al.
Epilepsia, 54(1), e5-e8 (2012-07-12)
Rufinamide (RUF) is a novel antiepileptic drug considered as second-line therapy in the treatment of Lennox-Gastaut syndrome. Treatment-emergent adverse events (AEs) have consisted mainly of drowsiness, irritability, vomiting, and loss of appetite. RUF is considered as a "weight-neutral" drug. We
Alberto Verrotti et al.
Pediatric neurology, 44(5), 347-349 (2011-04-13)
Rufinamide is a new orally active antiepileptic drug that has been found to be effective in the treatment of partial seizures and drop attacks associated with Lennox-Gastaut syndrome. We performed a quantitative analysis of the efficacy of this new antiepileptic
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service